LENSDNA OS
BACK TO HOME 🧬 PRIOR-AUTH DEMO 14-DAY PILOT
LENSDNA · HEALTHADMINDNA
PLATFORM · FIRST PRODUCT
COMPANY THESIS

Client-side execution
for work trapped
behind portals.

LensDNA is the client-side execution layer for work trapped behind portals, phone systems, SSO and VPNs. HealthAdminDNA is its first healthcare product, starting with prior authorization and appeals.
What this deck is selling: one residual prior-auth / UM workflow, a 14-day measured pilot, and the shared runtime that can host forthcoming vertical products. Financing terms belong in a tailored addendum.
01
WHY NOW
THE OPENING

Intelligence platforms already decide.
People still do the residual.

Healthcare PA / RCM / UM stacks are strong at “what should happen.” The remaining work still sits on operators inside payer portals, on phone calls, and in document workflows.
  • Decision layer is crowded and improving — policy engines, clinical decisioning, orchestration.
  • Execution layer is still manual — authenticated screens, attachments, status calls, appeal drafts, case memory.
  • That residual is the opening — measurable minutes, not another intelligence claim.
02
HEALTHADMINDNA
FIRST PRODUCT · CENTRE OF THIS DECK
CONCRETE FLOW

From approved case context to
submission-ready dossier.

HealthAdminDNA runs after the intelligence layer has decided. It executes residual non-API work and stops before irreversible action so the operator remains the approval gate.
01
Intelligence
Platform decides what should happen
02
Case context
Approved facts, attachments, policy surface
03
Execute residual
Portal DOM · voice calls · attachments
04
Human gate
Pause before irreversible actions
05
Dossier
Audit-ready case package
Hard rule: LensDNA / HealthAdminDNA does not replace clinical or payer decisioning. It executes approved residual work and keeps the operator in command.
03
PROOF
ONLY WHAT IS DEMONSTRATED
SYNTHETIC · INSPECTABLE

Wegovy · BCBS prior-auth
walkthrough is live.

  • Demonstrated path: intake → eligibility surface → medical-necessity narrative → telephony notes → step-therapy exception appeal → master case dossier.
  • Runtime pieces shown: optic / screen capture, authenticated DOM control, voice path, PDF dossier forge.
  • Guardrails shown: human approval gate; no real PHI; no clinical determination; submission stopped before the final action.
NEXT PROOF
What the first live pilot will measure — residual minutes, portal touches, phone minutes, exception rate, dossier completeness.
04
PILOT
ONE WORKFLOW · BINARY OUTCOME

One workflow. One owner.
14 days. Baseline first.

Define pass/fail before implementation. Measure residual work; do not claim broad efficiency until the baseline exists.
BASELINE
Handling minutes
Portal touches · phone minutes · exception rate · dossier completeness
RUN
14-day residual pilot
Same workflow with HealthAdminDNA + human approval gates
SCORE
Binary pass / fail
Agreed threshold in advance — not a platform tour
Buyer shape: prior-auth / UM ops owner at a health system, RCM vendor, or PA platform who can point to residual minutes still spent inside payer portals and on payer calls.
05
ENGAGEMENT MODEL
PILOT FIRST · EXPAND FROM PROOF
ENGAGEMENT MODEL

Pilot first.
Expand from measured proof.

Financing terms, use of funds and partner economics live in a tailored addendum or application response — not in the core product deck.
14-DAY WORKFLOW PILOT
One workflow · one owner · one baseline · one binary outcome
HealthAdminDNA (or another LensDNA product) is scoped around a recurring workflow still trapped in portals, phone systems, SSO/VPN environments or document processes. The baseline is agreed before implementation. The pilot measures handling minutes, system touches, phone minutes, exception rate and deliverable completeness.
EXPANSION PATH
Pilot → product surface
Pilot → workflow integration → repeatable product surface → additional verticals on the shared runtime.
COMMERCIAL PATHS
  • Paid workflow pilots
  • Product and integration partnerships
  • White-label or licensed deployments
  • Strategic platform relationships
WHAT COMES NEXT
HealthAdminDNA is the first product wedge. Additional vertical products follow once the relevant workflow has been proven. The same runtime supports healthcare, PropTech, industrial and robotics-adjacent execution.
06
FOUNDERS
HANS + JOLANDA · SWITZERLAND
CO-FOUNDERS

Hans builds the runtime.
Jolanda anchors the operation.

  • Hans Johannes Schulte — systems & product: ElevenLabs Startup Grant; WebRTC voice, optic, DOM execution, dossier forge. Ships the code and demos.
  • Jolanda Christina Maria Wevers — operations & stability: Operational bedrock and compliance posture so the wedge can be proven without distraction.
  • Surfaces: lensdna.app (product / pilot) · lensdj.app (builder / studio).
07
PLATFORM MAP
AMBITION WITHOUT CONFUSION
SHARED RUNTIME · SEQUENCED PRODUCTS

One runtime.
One fundable company now.

LensDNA proves technical depth. HealthAdminDNA is the company-shaped wedge. Other verticals are forthcoming products — not current revenue lines.
SHARED
LensDNA OS
Client-side execution runtime: optic, DOM control, WebRTC voice, case memory, PDF dossier forge, human approval gates, zero-retention design.
NOW
HealthAdminDNA
Healthcare spin-off. Prior-auth / UM residual. Synthetic proof live. 14-day pilot defined.
FORTHCOMING
Next products
PropTech, industrial / field, robotics-adjacent workflows — same runtime, later company or product lines after the healthcare wedge is proven.
08
NEXT STEP
PROOF BEFORE COMMITMENT

Run the residual path
before the pilot contract.

Synthetic Wegovy · BCBS workflow on HealthAdminDNA. Showcase for voice, optic, DOM, dossier. Public repo for code. Then a 14-day residual pilot with a binary threshold.
LensDNA

Hans Johannes Schulte

SYSTEMS · PRODUCT

Jolanda C. M. Wevers

OPERATIONS · STABILITY

lensdna.app · lensdj.app
hans@lensdj.app
@LensDJing
09
MOAT
WHAT WE OWN · CONFIDENTLY
CANONICAL LINE

We own the residual lane.
Not the whole market — this wedge.

We execute residual last-mile work under existing healthcare systems — human-gated and demoable — where operators still burn minutes in payer portals. A specialist-network SAFE funds that pilot and opens warm paths to those operators.
PRODUCT MOAT
Residual execution
Live under existing PA/UM stacks. Human approval before irreversible action. Synthetic Wegovy·BCBS proof on lensdna.app/healthadmindna. Optic · DOM · voice · dossier — not another decision engine.
DISTRIBUTION MOAT
Network SAFE
Specialist pre-seed membership is the ticket into the graph. Warm paths to PA/UM ops owners beat cold outreach. The check funds the pilot; the network feeds clients.
COMPOUNDING MOAT
Pilot → revenue
External residual baseline → measured pass/fail → more intros → paid workflow seats. Same runtime already ships prospect intel and other residual surfaces — depth without diluting the healthcare company story.
Confidence rule: we claim what is demoable and designed — residual execution, human gate, 14-day pilot. We do not claim full RCM ownership, zero-downtime production at scale, or multi-vertical revenue today.
10
APPENDIX A · SAFE ECONOMICS
INVESTOR ADDENDUM · NOT THE PRODUCT PITCH
PRE-SEED INSTRUMENT

~$150K SAFE · ~$2M post.
Network membership + pilot fuel.

Standard healthcare pre-seed band. Face check vs cash-to-company depends on membership/fee structure — plan runway on net.
POST-MONEY
$2.0M
Target pre-seed mark
SAFE FACE
~$150K
Post-money SAFE class
IMPLIED %
~7.5%
$150K ÷ $2M post
PLAN NET CASH
~$100K
If fees apply
USE OF FUNDS
  • 14-day residual pilot — one workflow, baseline first, binary pass/fail
  • Network activation — warm paths to PA/UM ops owners (clients first)
  • Founder runway — prove the wedge without distraction
  • Shared runtime — maintain HealthAdminDNA under LensDNA OS
WHY THIS SIZE
Matches stage: live residual demo, pilot design, no priced round yet. Stretch to $2M–$4M post only with design-partner signal or a second specialist check. Entity path: Delaware C-Corp as SAFE issuer.
A1
APPENDIX B · MARKET NUMBERS
RESIDUAL LANE · NOT ALL OF HEALTHCARE AI
PROBLEM POOL → SAM → SOM

~$35B PA admin burden.
We sell residual minutes.

Operators still burn time in portals after the intelligence layer decides. That residual is the market we address.
PROBLEM POOL (US)
~$35B
Est. annual prior-authorization administrative cost on the system. ~39 PA requests / physician / week · ~12–13 hours / week on PA work. Hospitals: tens of $B chasing denials, prior auths, documentation.
SAM (OUR LANE)
Low–mid $B
Software/services that remove residual portal, call, attachment and appeal work under existing PA/UM systems — not full RCM suites. PA automation market already multi-$B and growing; residual execution sits where APIs and decision engines stop.
SOM (NEAR-TERM)
→ low $M ARR
Path: 14-day pilots → paid workflow deployments with design partners over 2–3 years. Pre-seed is not priced on SOM; it is priced on proof + pilot design + network path to operators.
WHY NOW
CMS-0057-F pushes payers toward fully electronic prior authorization by January 2027 — a forcing function for residual exception and portal work decision engines still leave to operators.
WHAT WE DO NOT CLAIM
Entire US healthcare spend · full RCM market ($60B–$100B+ class) · “AI replaces utilization management.” We claim residual last-mile minutes under systems that already decide.
A2
APPENDIX C · SCOPE
WHAT THIS RAISE IS · WHAT IT IS NOT
CLEAR BOUNDARIES

One company-shaped wedge.
One pilot. One network.

THIS IS
  • HealthAdminDNA residual prior-auth / UM execution
  • Human-gated, demoable product on a shared runtime
  • 14-day pilot with baseline and binary outcome
  • Specialist-network SAFE as distribution moat + pilot fuel
  • Delaware C-Corp path for a clean SAFE issuer
  • Clients via warm PA/UM paths — revenue from residual work
THIS IS NOT
  • A multi-vertical platform raise
  • An architect-retainer or codebase-buyout menu
  • A request to fund PropTech / industrial / robotics revenue today
  • A claim to own all of RCM or “healthcare AI”
  • Outcome claims we cannot show live (minutes proven in pilot, not promised in the deck)
NEXT STEP
Open the residual path · then the pilot · then the SAFE
A3